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Abstract
Sporadic Creutzfeldt-Jakob disease (sCJD) is the most prevalent form of human prion disease and it is characterized
by the presence of neuronal loss, spongiform degeneration, chronic inflammation and the accumulation of
misfolded and pathogenic prion protein (PrPSc). The molecular mechanisms underlying these alterations are largely
unknown, but the presence of intracellular neuronal calcium (Ca2+) overload, a general feature in models of prion
diseases, is suggested to play a key role in prion pathogenesis.
Here we describe the presence of massive regulation of Ca2+ responsive genes in sCJD brain tissue, accompanied
by two Ca2+-dependent processes: endoplasmic reticulum stress and the activation of the cysteine proteases
Calpains 1/2. Pathogenic Calpain proteins activation in sCJD is linked to the cleavage of their cellular substrates,
impaired autophagy and lysosomal damage, which is partially reversed by Calpain inhibition in a cellular prion
model. Additionally, Calpain 1 treatment enhances seeding activity of PrPSc in a prion conversion assay. Neuronal
lysosomal impairment caused by Calpain over activation leads to the release of the lysosomal protease Cathepsin S
that in sCJD mainly localises in axons, although massive Cathepsin S overexpression is detected in microglial cells.
Alterations in Ca2+ homeostasis and activation of Calpain-Cathepsin axis already occur at pre-clinical stages of the
disease as detected in a humanized sCJD mouse model.
Altogether our work indicates that unbalanced Calpain-Cathepsin activation is a relevant contributor to the
pathogenesis of sCJD at multiple molecular levels and a potential target for therapeutic intervention.
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Introduction
Prion diseases are a large group of fatal rapid progressive
neurodegenerative diseases affecting both humans and
animals. The underlying mechanism leading to prion
pathogenesis is the conversion of the cellular prion pro-
tein (PrPC) into the abnormal disease-related form (PrPSc),
which accumulates in brain in form of insoluble
neurotoxic fibrous structures and amyloid plaques [2, 19].
Prion diseases are categorized according to their etiology
in sporadic, familial and iatrogenic forms. Sporadic
Creutzfeldt-Jakob disease (sCJD) accounts for about 85%
of all prion disease cases, it develops on patients without
any known risk factor or gene mutations [77] and it is
clinically characterized by the presence of dementia and a
broad range of pyramidal, extrapyramidal and cerebellar
signs [33, 89].
The combination of codon usage at position 129 of the
prion protein gene (PRNP) (Methionine or Valine) and the
electrophoretic mobility of PrPSc after Proteinase K (PK)
treatment (type 1 or 2), gives raise to different sCJD mo-
lecular subtypes characterized by the presence of specific
* Correspondence: franc.llorens@gmail.com
†Equal contributors
1Department of Neurology, University Medical Center Göttingen, and
German Center for Neurodegenerative Diseases (DZNE), Robert Koch Strasse
40, 37075 Göttingen, Germany
2German Center for Neurodegenerative Diseases (DZNE), Translational
Studies and Biomarkers, Site Göttingen, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Llorens et al. Acta Neuropathologica Communications  (2017) 5:35 
DOI 10.1186/s40478-017-0431-y
clinicopathological features [31, 73]. sCJD MM1 and VV2
are the most prevalent subtypes with more prominent cor-
tical and cerebellar affection, respectively.
Multiple cellular pathways have been described to be al-
tered in sCJD patients including neuroinflammation,
mitochondria function, protein synthesis machinery,
purine metabolism, endosomal-lysosomal system and
synaptic transmission, among others [4, 56, 59, 62]. In
addition, presence of endoplasmic reticulum (ER) and
oxidative stress [29, 71, 90, 95] as well as apoptotic mech-
anisms [27, 37, 55] is well-described in sCJD brain tissue
and in models of prion diseases. While it has not been
possible to ascertain the main molecular mechanism/s
contributing to the neurodegenerative process associated
with prion protein pathological conversion, the massive
imbalance of physiological functions could explain the
rapid progress of sCJD, which is usually fatal within a few
months of symptom onset. Thus, neuronal impairment
and associated neurodegenerative events are likely to
result from the combined and synergic deregulation of
multiple physiological processes and functions [54].
Therefore, studies aimed to unveil the very early and up-
stream events that unchain the cascade of pathological
mechanisms are necessary. In this regard, the recent
development of humanized sCJD mouse models recapitu-
lating pathological signatures occurring in humans have
been demonstrated to be useful in the analysis of the pre-
clinical aspects of sCJD pathology [62, 70].
A recurrent observation in prion disease models is the
presence of abnormally raised levels of cytosolic Ca2+.
Prion protein misfolding is one of the contributors to ER
stress, resulting in a fast release of Ca2+ from intracellu-
lar stores to the cytoplasm, an effect that is coupled to
the activation of the Unfolded Protein Response (UPR)
[46, 65, 90]. Indeed, several evidences point out for a key
role of ER stress and UPR activation in the occurrence
of synaptic dysfunction and neurodegeneration [91, 92],
as well as in the facilitation of prion spreading [44]. In
addition, the presence of abnormal or non-functional
PrP in the neuronal plasma membrane increases the per-
meability to physiological ions [60] and modulates the
expression and function of Ca2+ channels [57, 80]. Sus-
tained cytoplasmic Ca2+ elevation is associated with loss
of mitochondrial membrane potential, apoptotic and
necrotic death, and to the pathogenic activation of the
non-lysosomal cysteine proteases Calpains [47]. Patho-
genic Calpain activation has been implicated in normal
aging as well as in several acute neurological and neuro-
degenerative conditions, involving abnormal Ca2+ influx
[6, 18, 86, 98].In Alzheimer’s disease (AD) brain, in-
creased Calpain activation is widely reported [79, 93]
and immunoreactivity has been detected in senile pla-
ques [83] and neurofibrillary tangles [39]. Calpain-
mediated disruption of lysosomal membrane integrity
leads to the leakage of lysosomal Cathepsin proteases,
forming the basis of the so-called Calpain-Cathepsin axis
hypothesis [103]. Consequently, over activated Calpains
and Cathepsins lead to the proteolysis of target and non-
target cytoskeletal, cytosolic and nuclear proteins and
irreversible cellular damage that ultimately leads to
neuronal death [17, 88, 103]. Although evidence suggests
the existence of increased Calpain and Cathepsin S
expression in scrapie mice [22, 41], final proof of a
pathological Calpain-Cathepsin axis activation in prion
diseases is lacking.
Here, we present unambiguous evidence for an altered
Ca2+homeostasis in sCJD brain tissue and propose the
existence of the ‘Calpain-Cathepsin’ hypothesis, where
Ca2+-mediated activation of Calpains results in rupture
of lysosomes and leakage of killer Cathepsin S. These
mechanisms may act as multifaceted synergistic contri-
butors to the early pathological events of the disease
through unregulated cleavage of cellular substrates and




Anti-Ca2+/calmodulin-dependent protein kinase II (Cam-
KII)α and anti-CamKIIβ were from Zymed. Anti-
phospholipase C (PLC)ε, anti-Protein deglycase DJ-1
(DJ-1), anti-Cathepsin D, anti-B-cell lymphoma 2 (Bcl-
2), anti-BCL2 Associated X Protein (Bax), anti-Fas Cell
Surface Death Receptor (Fas), anti-Lysosomal associ-
ated membrane protein 2 (Lamp2) (H4B4), anti-
CCAAT-enhancer-binding protein homologous protein
(CHOP/GADD153), were from Santa Cruz. Anti-PLCγ
was from Neomarkers. Anti-S100A6, anti-Neurofilament
Light (NFL), anti-γ-tubulin and anti-β-actin were from
Sigma. Anti-Glyceraldehyde-3-Phosphate Dehydrogenase
(GAPDH), anti-Autophagy protein 5(ATG5), anti-
Activating transcription factor (ATF)4, anti-Glucose-
regulated protein, 78kDa (grp78), anti-X-box binding
protein 1(XBP1), anti-Fodrin, anti-calpastatin and anti-
calsequestrin 1 were from Abcam. Anti-inositol-requiring
enzyme 1 (IRE)1 and anti-microtubule-associated proteins
1A/1B light chain 3A (LC3) were from Cell Signalling.
Anti-Cystatin C, anti-CD68 (PG-M1) and anti-HLA-DR,
(TAL.1B5) were from Dako. Anti-p-IRE-1 (Ser724), anti-
Calpain 1, anti-Calpain 2 and anti-Cathepsin S were from
Thermo Fisher. Anti-ATF6 was from Enzo Life Sciences.
Anti-Brain-derived neurotrophic factor (BDNF) was from
Chemicon. Anti-hsp27 was from Stressgene. Anti-PrP
(SAF70) was from Spi-Bio, anti-PrP (3F4) was from
Millipore and anti-PrP (SAF32) was from Cayman.
Anti-Calpain 1 RP1 (N-ter) was from Triple Point Bio-
logics. Anti-phosphorylated neurofilaments (SMI-31),
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and anti-neurofilament H non-phosphorylated (SMI-
32) were from Covance.
Propidium Iodide was from Sigma, Calpain 1–2
activation kit was from Millipore. Prion protein peptide
106–126 was from JPT Peptides. MDL28170 was from
was from ENZO Life Sciences.
Human cases
Brain tissue was obtained from the Institute of Neuro-
pathology Brain Bank (HUB-ICO-IDIBELL Biobank) and
the Biobank of Hospital Clinic-IDIBAPS following the
guidelines on this matter of both Spanish legislation and
the local ethics committee. Neuropathological examin-
ation and characterization was carried out in every case
on paraffin-embedded samples. Detailed information of
neuropathology, inflammatory profiling and demographics
of the sCJD cohort is described as previously [61–63].
sCJD MM1 and VV2 cases were selected due to their
higher prevalence but different clinical phenotypes
[31, 73]. The presence of infectious, metabolic and
neoplastic diseases was discarded in control samples.
No correlation between post-mortem delay or sample
storage time and levels of proteins and mRNA
analysed was observed.
sCJD MM1 mice–tg340-PRNP129MM
The tg340 mouse line expressing about 4-fold level of
human PrP M129 on a mouse PrP null background was
generated as described before [70]. Control or sCJD
MM1 brain tissues as 10% (w/v) homogenates were in-
oculated in 6–10 week-old mice in the right parietal lobe
using a 25-gauge disposable hypodermic needle. Mice
were observed daily and the neurological status was
assessed weekly. The animals were sacrificed at pre-
symptomatic (pre-clinical: 120 dpi) and symptomatic
(early clinical: 160 dpi and late clinical: 183 dpi) stages.
Additionally, sCJD MM1 inoculum dilutions were per-
formed to study prolonged disease times; animals were
sacrificed at 210 dpi (10–1 dilution). A part of the brain
was fixed by immersion in 10% buffered formalin to
quantify spongiform degeneration and perform immuno-
histological procedures. The other part was frozen at
−80°C to extract protein and RNA. Survival time was
calculated for each isolate and expressed as the mean of
the survival day post-inoculation (dpi) of all mice scor-
ing positive for PrPSc. Infection rate was determined as
the proportion of mice scoring positive for PrPSc from
all inoculated mice. Every effort was made to minimize
detrimental effects on animals.
Primary cell cultures and treatments
For preparation of cortical neurons, pregnant Wistar rats
were killed by CO2-inhalation at embryonic day 18. The
brain from the embryos was taken and the cortex was
cleaned from surrounding brain tissue. The remaining
cortex was subsequently trypsinized with 1 ml 0.25%
Trypsin/EDTA (Gibco) for 12 min at 37°C. 50 μl DNase
I (Roche) was added and the tissue was dissociated using
a fire-polished Pasteur pipette. Cells were seeded on
poly-L-ornithine/laminin (Sigma)-coated glass cover
slips or directly on poly-L-ornithine/laminin-coated 24-
well culture plates in a density of 350.000 cells per well.
Cultures were maintained at 37 °C in a humidified
atmosphere at 5% CO2. Culture medium was based on
neurobasal medium (Gibco) containing additional trans-
ferrin (Applichem), penicillin/streptomycin/neomycin
(PSN) (Gibco), L-glutamine (Sigma), and B27 supplement
(Gibco). At day in vitro (DiV) 7, cells were treated with 5
μM MDL28170, when indicated, 1h before prion protein
peptide treatment (100 μM). Prion protein peptide was
prepared as reported before [13]. As control treatment
cells were incubated with equal concentration of non-
aggregated prion protein peptide. After 24 h of prion
protein peptide treatment, cells were analysed with Lyso-
tracker (ThermoFisher) following the manufacturer’s in-
structions. Calpain activity (Calpain assay kit – Millipore),
fixed with PBS-PFA 4% for immunohistochemistry or
collected for western-blot experiments. At 48h post-
treatment cell viability was analysed with Propidium
Iodide.
Western-blot
Tissues were lysed in Lysis Buffer containing: 100 mM
Tris pH 7, 100 mM NaCl, 10 mM EDTA, 0.5% NP-40
and 0.5% Sodium Deoxycolate plus protease and phos-
phatase inhibitors. After centrifugation at 14 000 g for
20 min at 4 °C, supernatants were quantified for protein
concentration (Bradford, Biorad), mixed with SDS-PAGE
sample buffer, boiled, and subjected to 8–15% SDS-
PAGE. Gels transferred onto PVDF membranes and
processed for specific immunodetection using ECL re-
agent. For comparative analysis using western-blot, 10
human cases per condition 4 mice per condition were
analysed. GAPDH and β-actin antibodies were used for
normalization.
RNA purification and retrotranscription
RNA from different human and mouse brain regions
was purified using miRVANA RNA isolation kit follo-
wing manufacturer’s protocol. RNAs were treated with
DNase Set (Qiagen) for 15min to eliminate genomic
DNA contamination. The concentration of each sample
was measured using a NanoDrop 2000 spectrophoto-
meter (Thermo Scientific). RNA integrity was assessed
with the RNA Integrity Number (RIN value) determined
with the Agilent 2100 Bioanalyzer (Agilent). The retro-
transcriptase reaction of the RNA samples was carried
Llorens et al. Acta Neuropathologica Communications  (2017) 5:35 Page 3 of 20
out with the High Capacity cDNA Archive kit (Applied
Biosystems).
RNA-sequencing
The analysis of RNA-seq data was performed as de-
scribed previously [43]. In brief, RNA-seq data was sub-
jected to an in-house quality control workflow. Read
quality was assessed using FastQC (http://www.bioinfor-
matics.babraham.ac.uk/projects/fastqc/) (v0.10.1) to
identify sequencing cycles with low average quality,
adapter contamination, or repetitive sequences from
PCR amplification. Alignment quality was analyzed
using samtools flagstat [58] (v0.1.18) with default param-
eters. RNA-seq data was aligned to the genome using
gapped alignment as RNA transcripts are subject to spli-
cing and reads might therefore span two distant exons.
Reads were aligned to the whole Mus musculus mm10
genome using STAR aligner [23] (2.3.0e_r291) with de-
fault options, generating mapping files (BAM format).
Read counts for all genes and all exons (Ensembl anno-
tation v72) were obtained using FeaturesCount (http://
bioinf.wehi.edu.au/featureCounts/). For data visualisa-
tion, BAM files were converted into WIG and BigWig
files using the MEDIPS ‘MEDIPS.exportWIG’ function
with a window of 50bp and RPM normalization. For the
differential expression analysis, read counts that were
generated with FeaturesCount were compared between
groups using DESeq2 [64]. Genes with a >0.5 logFC cut
off and FDR-adjusted p-value smaller or equal to 0.05
were considered to be differentially expressed.
qPCR
Quantitative RT-PCR assays were performed in duplicate
on cDNA samples in a LightCycler® 480 System from
Roche. The reactions were carried out using 20xTaqMan
Gene Expression Assays (Additional file 1: Table S1) and
2xTaqMan Universal PCR Master Mix (Applied Biosys-
tems). The reactions were conducted following the pa-
rameters: 50°C for 2 min, 95°C for 10 min, 40 cycles at
95°C for 15 s and 60°C for 1 min. The fold change was
determined using the equation 2-ΔΔCT. Mean fold-
change values were analysed with appropriate statistical
test indicated in each figure using GraphPad Prism 6.01.
Immunohistochemistry and immunofluorescence
Immunohistochemical study was performed on 4 μm-
thick dewaxed paraffin sections of control and sCJD
cases. Tissue sections were boiled in citrate buffer for 20
min to retrieve antigenicity. Endogenous peroxidases
were blocked with peroxidase (Dako) followed by 10%
normal goat serum. Following incubation with the pri-
mary antibody at room temperature overnight, the sec-
tions were incubated with EnVision + system peroxidase
(Dako) at room temperature for 15 min. The peroxidise
reaction was visualized with diaminobenzidine (DAB)
and H2O2. The omission of the primary antibody in
some sections was used as a control for the immuno-
staining; no signal was obtained with the incubation only
of the secondary antibody. No immunogenic peptides
were available for any antibody used. Sections were
slightly counterstained with haematoxylin.
Immunofluorescence for CamKIIβ, S100A6, Calpain1
and 2 and CHOP was carried out on de-waxed sections,
4 μm-thick, which were stained with a saturated solution
of Sudan black B (Merck, DE) for 15 min to block the
autofluorescence of lipofuscin granules present in cell
bodies, and then rinsed in 70% ethanol and washed in
distilled water. The sections were boiled in citrate buffer
to enhance antigenicity and blocked for 30 min at room
temperature with 10% foetal bovine serum diluted in
PBS. Then, the sections were incubated at 4°C overnight
with combinations of primary antibodies. After washing,
the sections were incubated with Alexa488 or Alexa546
(Molecular Probes, US) fluorescence secondary anti-
bodies against the corresponding host species. Nuclei
were stained with DRAQ5™ (1:2.000, Biostatus, UK).
After washing, the sections were mounted on Immuno-
Fluore mounting medium (ICN Biomedicals, US), sealed,
and dried overnight. Sections were examined with a
Leica TCS-SL confocal microscope. Again, omission of
the primary antibody in some sections was used as a
control for the immunostaining.
Double immunofluorescence for Cathepsin S, SIM32,
LAMP2, CD68 and HLA-DR were performed in 4%
formalin fixed and paraffin-embedded tissues from the
cerebellum of human sCJD. The 4μm-thick dewaxed
sections were treated for 60 min. with pH 6.0 citrate solu-
tion (Dako, DK) for antigen retrieval. The sections were
incubated at 4 °C overnight with combinations of primary
antibodies. As primary antibodies, anti-CD68 (1:50), anti-
cathepsinS (1:50), anti-LAMP2 (1:50), anti- phosphory-
lated neurofilaments (1:1000), anti-neurofilament H non-
phosphorylated (1:50), anti-HLA-DR, (1:20) were used.
The fluorescence-labelled secondary antibodies were
Alexa Fluor 488 (donkey anti-mouse, 1:200, Molecular
Probes, USA by Life Technologies) and Cy5 (goat anti-
rabbit, 1:100, Jackson ImmunoResearch, US). The follo-
wing combinations of antibodies were applied: CathepsinS
(Cy5)/CD68 (AF488), CathepsinS (Cy5)/LAMP2 (AF488),
CathepsinS (Cy5)/SMI 31 (AF488), CathepsinS (Cy5)/
SMI32 (AF488), and CathepsinS (Cy5)/HLA DRAF488).
Tissue slides were mounted with Prolong Gold antifade
reagent with DAPI (Molecular Probes by Life Technolo-
gies, US). The omission of the primary antibody was used
as a control for the immunostaining.
The staining results were evaluated with a confocal
laser-scanning microscope (FV1200, Olympus, Japan).
Image sizes of 1024 ~ 1024 pixels were obtained to allow
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for the greatest spatial discrimination between pixels
and maximise resolution potential in the XY dimension.
Transmission electron microscopy
For electron microscopy, approximately 2-mm3 samples
of grey matter from sCJD prefrontal cortex were pre-
pared. Wherever possible, at least two grids were pre-
pared from every block. The tissue blocks were
immersion-fixed in 2.5% glutaraldehyde for less than 24
h, embedded in Epon and routinely processed for elec-
tron microscopy. Grids were examined and photo-
graphed in JEOL JEM 100 CX and JEOL JEM 1011
transmission electron microscopes at 80 kV. Analysis of
fibril diameter was performed using iTEM Soft Imaging
System for transmission electron microscopy, Olympus,
Japan.
Immunoprecipitation
Immunoprecipitation experiments were performed by
using magnetic Dynabeads with protein G (Life Tech-
nologies) according to manufacturer’s instructions with
few modifications. Briefly, Dynabeads were equilibrated
with 0.3% CHAPS and antibody coupled for 30 min at 4
°C with slight rotation. 500 μg of tissue lysate was added
to the antibody-coupled Dynbeads and incubated for
overnight at 4 °C with slight rotation. Dynabead com-
plexes were washed three times with 0.3% CHAPS each
for 1 min. Elution was performed by resuspending com-
plexes in sample loading buffer (2X) and boiling at 95 °C
for 5 min.
Aggregation assays
Recombinant chimeric PrP (2 μg), which consists of the
Syrian hamster PrP (residues 14 to 128) followed by
sheep PrP (residues 141 to 234 of the R154 Q171 poly-
morphic haplotype) was incubated with 0.1% w/v brain
cell lysates from control and sCJD brains in the presence
or absence of proteases inhibitors cocktail (Roche) or
MDL28170. Reactions were performed at 30°C O/N with
soft shaking (150 rpm). Samples were either mixed with
LB (2x) and analysed by western-blot against PrP
(SAF70) antibody or centrifuged at 14000 rpm for 15
min at room temperature. Supernatant (soluble) and pel-
let (insoluble) fractions were quantified using Bradford
method. Four frontal cortex cases were analysed per
condition.
Solubility assay and subcellular fractionation
Solubility assays were performed as previously described
[32] with minor modifications. Brain samples (30mg)
from control and sCJD MM1 cases were homogenized
in a Polytron homogenizer (full speed) in 750 μL of ice-
cold PBS+ (sodium phosphate buffer pH 7.0, plus prote-
ase inhibitors) and centrifuged at 5.200 rpm at 4°C for
10-min. The pellet was discarded and the resulting
supernatant was centrifuged at 16500 g at 4°C for 90
min. The supernatant (S2) was kept as the PBS-soluble
fraction. The resulting pellet was re-suspended in a
solution of PBS, pH 7.0, containing 0.5% sodium deoxy-
cholate, 1% Triton, and 0.1% SDS, and this was centri-
fuged at 16500 g at 4°C for 90 min. The resulting
supernatant (S3) was kept as the deoxycholate-soluble
fraction. The corresponding pellet was re-suspended in a
solution of 2% SDS in PBS with occasional mixing and
maintained at room temperature for 30-min. Immedi-
ately afterward, the samples were centrifuged at 16500 g
at 25°C for 90 min and the resulting supernatant (S4)
was the SDS-soluble fraction. Fractions were analysed by
Western-blot for PrP and Calpain-1 antibodies as
described above.
Lysosome-enriched fraction and cytoplasmic fraction
were prepared from prion protein peptide treated and
untreated primary cell cultures. Samples were homoge-
nized in 0.25 M sucrose, 10 mM HEPES (pH 7.4), 100
mM EDTA, and centrifuged at 6500g, 4°C, for 5 min.
The supernatant was further centrifuged at 15000 g, 4°C
for 20 min. The pellet (enriched lysosomal fraction) and
the supernatant (cytoplasmic fraction) were mixed with
SDS-PAGE sample buffer.
RT-QuIC
The RT-QuIC was performed as described previously
[21, 81] with minor modifications. Recombinant PrP was
seeded with clarified 10% w/v brain homogenates lysed
in PBS 0.1% SDS and diluted 10–8 in PBS in a 96-well
black optical bottom plate (Fisher-Scientific). Each sam-
ple was run in duplicate. Prepared plates were sealed
(VWR) and incubated in a FLUO Star OPTIMA plate
reader (BMG Labtech) at 42°C for 80 h with intermittent
shaking cycles, consisting of one minute double orbital
shaking at the highest speed (600 rpm) followed by a 1-
min break. Beta-sheet formation kinetics was determined
by measuring the Thioflavin-T (ThT) fluorescence signal
(450 nm excitation and 480 nm emission) every 30 min
in relative fluorescence units (rfu). In vitro proteolytic
assays with active human Calpain 1 (Millipore) were per-
formed on 1% (w/v) brain lysates for 30 min at 37°C in
buffers recommended by commercial suppliers.
Statistical analysis
Pearson r and statistical significance (p value) was
calculated to indicate correlations between different
groups of samples. The ANOVA was followed by a
Tukey’s Multiple Comparison post-hoc test when
values from different groups were compared. Un-
paired two-tailed t-test was used when two groups of
samples where compared. GraphPad Prism 6.01 was
used for statistical calculations. Differences between
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groups were considered statistically significant at * p
< 0.05, ** p < 0.01, and *** p < 0.001.
Results
Altered Ca2+ homeostasis and ER stress in sCJD brain
To identify differentially expressed genes during develop-
ment of sCJD pathology we analysed the expression levels
in the cortical region of tg340-PRNP129MM mice infected
with sCJD MM1 brain homogenates at pre-clinical (120
dpi) and clinical (180 dpi) stages and compared with those
obtained from control infected animals. These mice are an
excellent model of sCJD pathogenesis since they fully re-
capitulate the neuropathological and molecular features of
sCJD MM1 subtype cases [15, 62, 70].
Analysis of RNA-sequencing indicated a massive deregu-
lation of Ca2+ related genes in sCJD infected mice, espe-
cially at clinical stages (Fig. 1a). Among them, we detected
Ca2+ binding proteins, Ca2+ channels and Ca2+-dependent
cellular responses, suggesting an alteration of Ca2+ homeo-
stasis. Selected mouse genes falling into these categories
were validated by qPCR: downregulation of the Ca2+-
release channel Ryanodine receptor 1 (RYR-1), and upreg-
ulation of the Ca2+-binding proteins S100 Ca2+-binding
protein (S100)B and S100A6, the heat shock protein family
B (Small) member 6 (hspb6/hsp20), the Ca2+-responsive
Fas gene and the nuclear Ca2+ signalling target AMP-
dependent transcription factor (ATF)3, were confirmed
(Fig. 1b).
Next we validated at protein level in sCJD the
alteration on Ca2+-response proteins previously detected
in the RNA-seq analysis (Fig. 1c and d). Downregulation
of Phospholipase C (PLC)γ and Ca2+/calmodulin-
dependent protein kinase II (CamKII)β, but not of Cam-
KIIα, and upregulation of PLCε, and S100A6 proteins
was detected by western-blot in sCJD cases compared to
controls (Fig. 1c). Lower levels of CamKIIβ in neurons
a b c
d
Fig. 1 Altered Ca2+ homeostasis in sCJD. a Heat map analysis of regulated Ca2+ related genes in the cortical region of the tg340-PRNP129MM
sCJD mice at 120 (pre-clinical) and 180 (clinical) days after inoculation with sCJD MM1 brain homogenates compared with control inoculated
mice. Data were generated by RNA-sequencing analysis as indicated in material and Methods section. Regulated genes were considered those
with log2FC superior or equal to 0.5 and p value <0.05. b qPCR validation of selected genes involved in Ca2+–dependent cellular responses at
120 dpi and 180 dpi in the sCJD infected tg340 mice. Four to five animals were analysed per time point and condition. c Western-blot (n = 14/
group) and (d) immunohistochemistry validation in human sCJD MM1 cases from selected proteins regulated in the sCJD infected tg340 mice.
Unpaired t-test (95% CI) was used for the comparisons of the two groups. *p < 0.05; **p < 0.01; ***p < 0.001
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and increased S100A6 in reactive astroglia and neurons
in sCJD were further detected by immunohistochemistry
analysis (Fig. 1d).
Since a link between ER stress responses and Ca2+
homeostasis has been suggested in prion diseases [91]
we next analysed activation state of the UPR, which is
activated in prion disease models [46, 68]. No significant
differences were observed in the levels of CCAAT-
enhancer-binding protein homologous protein (CHOP/
GADD153) between control and sCJD cases in human
and mice (Additional file 2: Figure S1A, B and C). No al-
terations in the cleavage of ATF6 from the full length
(p90) to the cleaved form (p50) were observed. However,
significant increase in the IRE-1 phosphorylation was de-
tected in sCJD without a concomitant increased expres-
sion of total IRE-1 (Additional file 2: Figure S1A). Partial
UPR response coupled to the upregulation of the UPR/
ER related proteins grp78, hsp27 and Bcl-2 and the Ca2+
responsive proteins BDNF and Fas in sCJD without al-
teration of Bcl-2/Bax ratio (Additional file 3: Figure S2A
and B) indicates the existence of a complex stress-
related cascade of Ca2+-dependent responses in human
prion pathogenesis.
Deregulated expression and activation of Calpains in sCJD
Increase in intracellular Ca2+ concentration leads to the
activation of the Ca2+-dependent non-lysosomal cysteine
proteases Calpains, which are over activated in several
pathological conditions including neurodegenerative dis-
eases [26, 47]. Thus, Calpain expression and activation
state was analysed in sCJD. At mRNA expression level,
Calpain 2 (CAPN2) was overexpressed in the frontal
cortex and cerebellum of sCJD MM1 and VV2 subtypes.





Fig. 2 Regional and subtype-dependent expression and activation of Calpains in sCJD. a qPCR analysis of expression levels of Calpain 1 and Cal-
pain 2 in the frontal cortex and cerebellum of control, sCJD MM1 and sCJD VV2 cases. b Western-blot and densitometry of Calpain 1 and Calpain
2 in the frontal cortex and cerebellum of control, sCJD MM1 and sCJD VV2 cases (n = 14/group). c Calpain activity by means of fluorometric assay
based on the detection of cleavage of Calpain substrate Ac-LLY-AFC in the frontal cortex of control, sCJD MM1 and sCJD VV2 cases (n = 6/group).
d Western-blot and densitometric analysis of Fodrin and N-terminal cleaved Calpain-1 in the frontal cortex of control, sCJD MM1 and sCJD VV2
cases (n = 6/group). ANOVA test followed by post-test Tukey’s Multiple Comparison Test was used to compare the values from different groups. P
values for the comparisons of the three groups are indicated in the figure:*p < 0.05; **p < 0.01; ***p < 0.001
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(CAPN1) levels in the cerebellum of sCJD MM1 cases,
no major alterations were detected for Calpain 1 (Fig. 2a)
and for the small regulatory Calpain subunit 4 (CAPN4/
CAPSN1) (Additional file 4: Figure S3A). Analysis at
protein level matched data obtained at mRNA level. In
addition, the presence of autolytic Calpain 2 bands was
found in sCJD cases as an indirect observation of in-
creased Calpain activity (Fig. 2b). Fluorescent enzymatic
activity assays demonstrated an increase of Calpain 1/2
activity in the frontal cortex of sCJD MM1 cases com-
pared to controls. Increased Calpain activity was also ob-
served in sCJD VV2 cases compared to controls, but
without reaching statistical significance (Fig. 2c). De-
creased Calpain 1 levels detected with an antibody for
the N-terminal region that is cleaved on its activation
process (Fig. 2d) support Calpain activation in sCJD
brain. Additionally, sCJD cases presented increased
Fodrin (Fig. 2d) and Neurofilament Light (NFL) cleavage
and decreased γ-tubulin levels, both known cellular
endogenous Calpain substrates (Fig. 2e and Additional
file 4: Figure S3B).
In order to determine the neural cell type expres-
sion and subcellular localization of Calpains in sCJD
brains, double immunohistochemistry analysis with
neuronal and glial markers as well as solubility assays
were performed. Calpain expression in CD68+ and
GFAP+ cells was residual both in the frontal cortex
and cerebellum regions of sCJD cases (Fig. 3a and b).
On the contrary, Calpain 1 expression was predomin-
ant in MAP2+ cells (Fig. 3c). In control cases,
Calpain 1 was localized in the cytoplasmic fraction
(S2); while PrP was mainly present in membrane
fractions (S3), despite being detectable in the cyto-
plasmic (S2) and SDS-soluble fractions (S4) (Fig. 3d).
In sCJD, Calpain 1 levels were increased in the S3
and S4 fractions in agreement with Calpain activation
at the cell membrane following interaction with
membrane bound phospholipids [25]. As expected, in-
creased PrP levels in sCJD were detected in the SDS
soluble fractions as a consequence of its increased





Fig. 3 Neuronal localization of Calpains in sCJD. a Immunohistochemical staining of frontal cortex and cerebellum sCJD stained either with
Calpain 1 (green) and Iba-1 or GFAP (red). Tissues were counterstained with DAPI (blue). b Immunohistochemical staining of cerebellum sCJD
stained with Calpain 2 (green) and Cd68 (red). Tissues were counterstained with DAPI (blue). c Immunohistochemical staining of frontal cortex
sCJD stained with Calpain 1 (green) and MAP2 (red). Calpains are mainly expressed in neurons as shown in the merged panels. d Western-blot
analysis of solubility assays in control (n = 3) and sCJD MM1 cases (n = 3) by means of differential centrifugation in which cytoplasm fraction (S2),
membrane fraction (S3) and insoluble fraction (S4) were obtained. Samples were developed for Calpain1 and PrP antibodies. . Unpaired t-test
(95% CI) was used for the comparisons of the two groups. *p < 0.05; **p < 0.01; ***p < 0.001
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Impairment of lysosomal integrity and autophagy
function in sCJD
The pathogenic activation of Calpain in the intracellular
compartment leads to a broad range of degenerative
conditions in the brain [96]. Among them, Calpains in-
duce lysosomal permeabilization and disruption as a
consequence of the unspecific cleavage of membrane
proteins [88, 97]. The presence of neuronal processes
filled with autophagosomes and lysosomes, distorted
lysosomes, abnormal lysosomes and auto-lysosomes was
a general feature in the analysis of sCJD cases by
Transmission electron microscopy (TEM) (Fig. 4a). This
was accompanied by the expression of autophagy re-
lated genes in the tg340-PRNP129MM -sCJD mice
(Additional file 5: Fig. S4A and B) and in sCJD cases
(Additional file 5: Figure S4C and D). The increase in
LC3 II, DJ-1 as well as of the heat shock proteins
HSPA8 and HSPB8 detectable in sCJD, along with de-
creased ATG5 and unaltered LAMP2 levels (Additional
file 5: Figure S4C and 4D) suggested that, although
autophagy mechanisms may be switched in sCJD, this
process is not fully functional, in agreement with the
presence of abnormal autophagy vesicles (Fig. 5a).
To test the role of Calpain activation in lysosomal dis-
ruption, primary cortical neurons (PCC) were treated
with the aggregated prion protein peptide 106–126, an
ex vivo model of prion toxicity leading to synaptic dam-
age and neurotoxicity [40, 67]. Prion protein peptide
treatment did not alter Calpain 1 expression (Fig. 4b)
but induced an increase in Calpain activity; resembling
observations in sCJD (Fig. 4c). In addition, prion protein
peptide treatment impaired lysotracker signal suggesting
lysosomal dysfunction in peptide-treated neurons, an ef-
fect that was partially reverted by the addition of the
Calpain inhibitor MDL28170 (Fig. 4d). Accordingly,
MDL28170 also significantly protected neurons from
prion protein peptide mediated toxicity (Fig. 4e).
Calpain activity modulates Prion conversion
In addition to the well-known neurotoxic effects of Cal-
pain over activation in pathological conditions, Calpain





Fig. 4 Abnormal lysosomes in sCJD are dependent on Calpain over activation. a TEM images indicating the presence of processes with
autophagosomes and lysosomes, distorted and abnormal lysosomes and auto-lysosomes in neurons of the frontal cortex of sCJD cases. b and c
Increased Calpain 1/2 activity by fluorimetric Calpain activity (c) without alterations on Calpain 1 levels (b) in PCC treated with the prion protein
peptide (106–126). Inhibition of Calpain activity by MDL28170 treatment partially reverses (d) decrease on Lysotracker signal and decrease on cell
viability (e) caused by prion protein peptide treatment. Unpaired t-test (95% CI) was used for the comparisons of the two groups. Data from PCC
are obtained from three independent experiments. ANOVA test followed by post-test Tukey’s Multiple Comparison Test was used to compare the
values from different groups. P values for the comparisons of the three groups are indicated in the figure:*p < 0.05; **p < 0.01; ***p < 0.001
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Calpain inhibition prevents the accumulation of PrPSc in
prion models [101]. Thus, activation of Calpain in sCJD
cases prompted us to speculate a potential role of Cal-
pain in the PrPSc mediated pathogenesis.
Incubation of recombinant PrP (rPrP) with sCJD brain
extracts showed an increase in the formation of SDS-
PAGE resistant oligomeric rPrP forms compared to in-
cubation with control brain extracts (Additional file 6:
Fig. S5). To demonstrate the role of proteases in PrP ag-
gregation, solubility assays were performed with rPrP in-
cubated with sCJD extracts in the presence and absence
of protease inhibitors and MDL28170. Both treatments
reduced the amount of insoluble rPrP formed upon its
incubation with sCJD extracts (Fig. 5a).
In order to analyse if exacerbated proteolytic activ-
ities were altering not only PrP aggregation but also
its seeding ability, brain extracts were incubated with
recombinant Calpain. Resulting reactions were used
as a seeding material for real-time quaking-induced
conversion (RT-QuIC) assays, an vitro amplification
technology for detection of the abnormal form of
prion protein (PrPSc) and the quantification of its
prion-seeding activity [5, 21, 66] as well as for the
characterization of compounds inhibiting or enhan-
cing PrP conversion [81].
Increased fluorimetric signal as measured by the quan-
tification of the resulting Area Under the Curve (AUC)
and decreased lag phase indicated that Calpain activity
in sCJD lysates enhanced PrP seeding ability over rPrP
compared to non-treated lysates (Fig. 5b). Additionally,
pre-treatment of tg340-PRNP129MM sCJD mice brain
extracts with MDL28170 reduced RT-QuIC signal (de-
creased AUC and increased lag phase), in a dose
dependent manner (Fig. 5c). To validate the specificity
of pathogenic PrP as seeding agent in the RT-QuIC reac-
tions performed in the presence of Calpain, the anti-
prion compound doxycycline (DOX) [81] was added into
the assay, which completely inhibited fluorimetric signal
(Additional file 7: Fig. S6).
The observation of Calpain accumulations in the
cerebellum of sCJD tissue suggested that Calpain may be
involved in the physiopathological mechanisms of PrP
aggregation forming stable protein-protein complexes,
not limited to an enzyme-substrate interaction. Immu-
noprecipitation experiments demonstrated that Calpain




Fig. 5 Calpain-dependent PrP solubility and prion conversion in sCJD. a Solubility assay in sCJD brain homogenates (n = 3) in presence of
recombinant PrP (rPrP) and in the presence or absence of protein inhibitors and the Calpain inhibitor MDL28170. Quantification of soluble rPrP is
shown. b RT-QuIC assay performed in the presence of sCJD brain homogenates (n = 4) as seeding material, previously treated or untreated with
recombinant Calpain. Area under the curve (AUC) (left) and Lag Phase (hours) are shown. c RT-QuIC assay from tg340-PRNP129MM brain extracts
(n = 3) inoculated with sCJD MM1 previously incubated with increased concentrations of MDL28170. Relative Fluorescence Units (RFU) are shown
(d) Co-immunoprecipitation study of Calpain 1 and PrP in the frontal cortex of sCJD MM1 and in the cerebellum of sCJD VV2 cases. Calpain 1
antibody was used for western-blot immunodetection. Control indicates the use a non-specific antibody as immunoprecipitating antibody.
Unpaired t-test (95% CI) was used for the comparisons of the two groups. ANOVA test followed by post-test Tukey’s Multiple Comparison Test
was used to compare the values from different groups. P values for the comparisons of the three groups are indicated in the figure:*p < 0.05;
**p < 0.01; ***p < 0.001
Llorens et al. Acta Neuropathologica Communications  (2017) 5:35 Page 10 of 20
and only slight signal was detected in the cerebellum re-
gion, ruling out the possibility of a functional interaction
between both proteins (Fig. 5d).
Cathepsin S activation in sCJD
The demonstration of neuronal lysosomal disruption in
sCJD made us speculate that release of lysosomal con-
tent, especially Cathepsins, could be a key determinant
on the neurotoxicity linked to prion diseases through
the so-called Calpain-Cathepsin hypothesis observed in
some neurological and neurodegenerative conditions
[88, 103]. We profiled the complete Cathepsin family
signature in the cortex of the tg340-PRNP129MM sCJD
mice from the RNA-seq dataset at clinical stages. Eight
members of the Cathepsin family as well as their en-
dogenous inhibitor Cystatin C appeared overexpressed
compared to controls (Fig. 6a). Among upregulated Ca-
thepsins, Cathepsin S retaining proteolytic activity at
neutral pH [53], and Cathepsin D, associated with in-
creased risk of variant CJD [10] and with enhanced im-
munoreactivity in sCJD [56], were initially explored. In
addition, both genes were previously reported to be up-
regulated in scrapie infected mice [22, 100]. Overexpres-
sion of Cathepsin S, especially in the frontal cortex, as
well as the presence of mature (active) Cathepsin S
bands, was detected in sCJD irrespective of the brain re-
gion and disease subtype, in agreement with our previ-
ous observation of increased Cathepsin S mRNA in
sCJD [62]. Moderate increase in Cathepsin D was de-
tected in the frontal cortex of sCJD MM1 cases and in
the cerebellum of sCJD VV2 cases (Fig. 6b). Neuronal
Cathepsin S was principally localized in the axons, al-
though some staining in the soma was also detectable
(Fig. 7a). Only partial overlap between Cathepsin S and
the lysosomal marker LAMP2 staining was detected
(Fig. 7b) indicating that Cathepsin S is mainly located
outside the lysosomal compartment in sCJD, in agree-
ment with the presence of lysosomal damage (Fig. 4a).
Although it was technically not possible to detect PrP-
Cathepsin S colocalization in sCJD neurons, three differ-
ent PrP antibodies did immunoprecipitate Cathepsin S
from sCJD brain extracts (Fig. 7c). Additionally, in PCC
Cathepsin S localized in granule-like cytoplasmic
regions, while treatment with the prion protein peptide
induced changes in the immunofluorescence signalling
to a diffuse staining pattern in the neuronal soma
suggesting Cathepsin S release from intracellular
organelles (Fig. 7d). Accordingly, lysosomal enriched
fractions derived from prion protein peptide treatments
presented a decrease in Cathepsin S content, while a
slight increase in cytoplasmic fraction could be detected
(Additional file 8: Figure S7).
Our immunohistochemical analysis revealed no major
alterations in neuronal Cathepsin S levels in sCJD brain
tissue and prion protein peptide treated PCC, which
stands in clear contrast with elevated total expression
levels by qPCR and western-blot. Since Cathepsin S is
involved in a broad range of inflammatory-related
pathological stimuli [20], the presence of a secondary
role for Cathepsin S in glial cells of sCJD was investi-
gated. Immunohistochemistry analysis revealed a major
Cathepsin S microglial staining in sCJD (Fig. 8a). These
observations were validated in double Cathepsin S-
CD68 and Cathepsin S-HLA-DR immunostainings
(Fig. 8b) and further confirmed by the finding that
Cathepsin S mRNA levels correlated with those of
microglial markers (AIF1 and CD68), while no corre-
lation was observed with the astrocytic marker GFAP
(Fig. 8c). The analysis of the Cathepsin S expression
levels by qPCR in the frontal cortex of several neurode-
generative diseases with cortical affection indicated that
Cathepsin S sCJD overexpression is not a common fea-
ture of neurodegenerative diseases, although modest in-
creases on its expression was also detected in Parkinson
Disease/Lewy Body Dementia (PD/LBD) and in early
stages of AD (Fig. 8d).
Activation of Calpain-Cathepsin axis is an early event in
sCJD pathogenesis
Time-dependent alterations of Calpain-Cathepsin axis in
sCJD pathogenesis were analysed in the tg340-
PRNP129MM sCJD mice. Increased mRNA Calpain
levels were detected at differential disease stages with
exception of a decrease of cerebellar Calpain 1 levels at
180 dpi (Fig. 9a). However, alterations at mRNA levels
were not translated into major changes at protein level,
besides a slight increase in the expression of autolytic
bands in sCJD infected animals (Fig. 9b) in agreement
with observations in human samples. Decreased levels of
Calpain 1, detected by a Calpain N-terminal directed
antibody indicated the presence of active Calpain at pre-
clinical and especially at clinical stages of the disease.
Analysis of endogenous Calpain inhibitors expression
revealed the presence of increased Cystatin C at clinical
stages of the disease, but unaltered Calpastatin levels
(Fig. 9c).
Increase in Cathepsin S mRNA and protein was de-
tected at pre-clinical sCJD stages, and more significantly,
at clinical stages (Fig. 9d). Importantly, the presence of
cleaved Cathepsin S mature bands was already present
at pre-clinical sCJD stages (Fig. 9b). Alterations in Cal-
pain and Cathepsin expression levels and their activation
at pre-clinical stages correlate with the presence of
pathogenic PrP, in form of Proteinase K-resistant PrP
(PrPres), whose levels are already detectable at pre-
clinical stages but in lower amounts (5 times lower) than
at clinical stages (Fig. 9e).
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All together indicates that Calpain and Cathepsin S ac-
tivation are parallel events during development of sCJD
and that Calpain-Cathepsin axis activation is an early
event in disease pathogenesis.
Discussion
As a consequence of the conformational changes in PrPC
leading to the formation and accumulation of pathological
PrP forms (PrPSc), multiple mechanisms operate in a con-
certed manner promoting the spread of the disease
throughout the brain and the manifestation of the prion-
related pathology. The nature of the primary contributors
to neurodegeneration in prion infected neurons is unclear,
since many molecular mechanisms and cellular pathways
are simultaneously altered and acting interconnected in a
synergic manner [54]. In addition, initial neuroprotective
events, such as neuroinflammation, may become toxic
after pathological threshold has been reached [1].
Plasma and ER membrane channel receptors and
intracellular Ca2+ sensors play a key role in maintaining
a
b
Fig. 6 Altered Calpain levels in sCJD. a Expression of Cathepsin family, Calpain 1 (Capn1), Calpain 2 (Capn2) and Calpain 4 (Capns1) in the cortical
region of the tg340-PRNP129MM mouse model at 180 (clinical) days after inoculation with sCJD MM1 brain homogenates. Data were generated
by RNA-sequencing analysis. Fold Change line at 1.5 indicates the threshold of significant regulations in the expression levels for these genes
between control and sCJD MM1 inoculated mice. b Western-blot and densitometry analysis of Cathepsin S and Cathepsin D expression in the
frontal cortex and cerebellum of control (n = 9), sCJD MM1 (n = 9) and sCJD VV2 (n = 9) cases. ANOVA test followed by post-test Tukey’s Multiple
Comparison Test was used to compare the values from different groups. P values for the comparisons of the three groups are indicated in the
figure:*p < 0.05; **p < 0.01
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physiological Ca2+ concentrations in the cytoplasm.
When Ca2+ homeostasis is unbalanced, sustained in-
crease in cytoplasmic Ca2+ is a common initial step of ir-
reversible injury in neurons [35]. The presence of altered
Ca2+ homeostasis has been suggested in prion models
[91] although experimental evidence of its occurrence in
human prion diseases was not reported so far. In sCJD
brain tissue we detected massive alterations in the ex-
pression levels of Ca2+-dependent genes, including Ca2+
binding proteins, plasma membrane and ER Ca2+ recep-
tors and Ca2+ signalling genes. While these regulations
were mainly detectable at clinical stages of the disease,
alterations in the expression of several Ca2+-related
genes were also found at pre-clinical stages, when accu-
mulation of pathological PrP in form of PrPres was also
detected. This is in agreement with recent data suggest-
ing that disturbed Ca2+ homeostasis and Ca2+-mediated
signalling is a common feature in early stages of several
neurodegenerative diseases such as PD and AD [48, 50,
87, 99]. Additionally, in AD, disrupted neuronal Ca2+
homeostasis exacerbates Aβ formation and promotes tau
hyper-phosphorylation [9].
The primary reason of altered Ca2+ homeostasis in sCJD
is not clear, but accumulation of misfolded PrP and conse-
quent malfunction of protein quality control machinery
could lead to deregulation of intracellular Ca2+ [90, 91].
Several mechanisms can contribute to increased Ca2+
influx from the extracellular space: i) the presence of re-
active oxygen species; as a consequence of oxidative stress
[24], a main hallmark in prion pathogenesis [11, 29], ii)
loss of PrPC function in the plasma membrane, leading to
an impairment of the neuroprotective role of PrPC as
modulator of glutamate receptors [14, 52] and iii) the
presence of soluble PrP amyloid oligomers binding to cel-
lular receptors leading to disruption to the cell membrane
and formation of pores in the cell membrane leading to
calcium influx [16, 51, 85].
Our observations indicate that a pleiade of Ca2+-re-
lated genes present an altered expression in sCJD.
Ca2+ binding proteins (i.e.: S100 family members,
calsequestrin, smoc1 and cabp7) and Ca2+-regulated
genes (i.e.: BDNF, Bcl-2 and ATF3) were upregulated
in sCJD, while Ca2+ and cation channels (i.e.: Cacn
family members, RyR1, Itpr1) displayed decreased
levels compared to controls. Elevated expression of
Ca2+ binding proteins may be a neuroprotective
response to buffer excess of intracellular Ca2+, as it
occurs under excitotoxic conditions [78]. Interestingly,
regulation of Ca2+ related proteins is not restricted to
neuronal cells and thus, increased immunoreactivity
of Ca2+ binding proteins such as S100A6 was also de-
tected in reactive astrocytes where S100A6 upregula-
tion may play a role in glutamate toxicity [102].
Increased S100A6 levels have also been reported in
a b
dc
Fig. 7 Neuronal Cathepsin S in sCJD. Immunohistochemical staining of FC sCJD cases double-immunostained with Cathepsin S (red) and (a)
SIM32 (green) or LAMP2 (b). Tissues were counterstained with DAPI (blue). c Co-Immunoprecipitation study of Cathepsin S and PrP in the frontal
cortex of sCJD cases. Three different anti-PrP antibodies recognizing independent epitopes were used for Immunoprecipitation (3F4, SAF32 and
SAF70). Western-blots were developed with a Cathepsin S antibody. Control indicates the use a non-specific antibody as immunoprecipitating
antibody. d Immunohistochemistry images of Cathepsins S (green) in PCC treated or untreated with the prion peptide. Cells were counterstained
with DAPI
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other neurodegenerative diseases such as AD and
ALS [12].
Alteration of neuronal Ca2+ homeostasis in prion
disease models induces the release of stored ER- Ca2+
leading to ER stress, which is associated with the upreg-
ulation of several ER-chaperones and to an increase of
the UPR when subjected to ER-stressors [44, 90]. Indeed,
chronic ER stress emerges as a key pathological mecha-
nism in prion pathogenesis, not only for its contribution
to neurotoxic mechanisms but also to prion spreading,
since Ca2+ dependent ER-stress facilitates prion replica-
tion [44] and cells expressing familial CJD related PrP-
mutants present abnormal Ca2+ content and increased
susceptible to ER stress-inducing agents than controls
[90]. Our study supports the presence of altered Ca2+
homeostasis and ER stress together with a partial activa-
tion of UPR response in sCJD, being IRE-1 pathway the
only UPR contributing branch. This would be in agree-
ment with the previously reported lack of activation of
the PERK-eIF2α in sCJD, in contrast to what is observed
in AD [94] suggesting the presence of specific ER-stress
responses in both diseases. Importantly, IRE-1 has been
connected to the autophagy mechanisms that contribute
to the eventual apoptotic fate through caspase cascade
activation [82] but genetic targeting of its downstream
effector XBP-1 did not affect prion replication or patho-
genesis [45]. This suggests that the IRE-1/XBP-1 UPR
branch, which is activated in human prion diseases as
demonstrated in the present work, may not contribute
to the occurrence of prion pathology. Interestingly, our
study also validates the presence of elevated levels of
grp78, a master regulator for ER stress and UPR activa-
tion, which has been recently shown to modulate prion
propagation in vitro and in vivo [74].
Other consequences of intracellular Ca2+ overload are
mitochondrial damage, and deregulation of Calpains
activity [34, 36, 88]. While decline in mitochondrial
machinery has been recently demonstrated in sCJD [4]
over activation of Calpains in prion disease has only
been suggested in scrapie infected mice [38, 41]. By
complementary means we demonstrated the presence of
exacerbated neuronal Calpain activity in sCJD brain,
which, in turn, mediated lysosome damage or rupture
and cell death, both effects partially reversed by a Cal-
pain inhibitor. Additionally, we observed that inhibition
of proteolytic activity increases PrP solubility, while Cal-
pain treatment is able to enhance prion conversion by
fostering the seeding ability of PrPSc over physiological
PrP, a factor that can contribute to the rapid prion repli-




Fig. 8 Microglial overexpression of Cathepsin S in sCJD. a Immunohistochemical analysis of Cathepsin S expression in cerebellum of sCJD cases
showing microglial localization. b Immunohistochemical staining of sCJD cases in the frontal cortex double-immunostained with Cathepsin S
(red) and CD68 (green) left and Cathepsin S (red) and HLA-DR (green) right. Tissues were counterstained with DAPI (blue). c Correlations between
the levels of Cathepsin S and glial markers (AIF1 and CD68 for microglia and GFAP for astroglia) in the frontal cortex of sCJD cases. R and p values
(Pearson correlation) are indicated. d Expression levels of Cathepsin S in the frontal cortex of several neurodegenerative diseases with known
cortical affection by means of qPCR analysis FFI: Fatal Familial Insomnia, PD-LBD: Parkinson Disease-Lewy Body Dementia, AD: Alzheimer’s Disease,
Braak Stages I-II and III-IV, PSP: Progressive supranuclear palsy, FTD: Frontotemporal dementia, Pick: Pick’s disease. P values for the comparisons of
the disease groups with control cases are indicated in the figure:*p < 0.05; **p < 0.01; ***p < 0.001
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agreement with the reported proteolytic activity of
Calpain over PrPSc. In scrapie infected mice, Calpain in-
hibition did not only prevent the Calpain-mediated
cleavage of PrPSc and its accumulation, but also
increased the disease incubation time [101]. Indeed,
multiple lines of evidence support a role for proteolytic
PrPSc cleavage in the neurotropism and phenotypic
expression of prion diseases [30, 49, 72].
Additionally, lysosomal damage due to the presence of
free radicals derived from oxidative stress and proteolysis
of ion channels would turn into depolarization of neurons
creating a synergic effect in Ca2+ influx in form of a self-
perpetuating loop, leading to the pathogenic activation of
several mechanisms responding to these insults, such as
ER stress, autophagy, oxidative stress and chronic neuro-
inflammation, which are known mechanisms contributing
to prion pathogenesis [28, 29, 46, 59, 62, 84]. Interestingly,
our data suggest the presence of activated but impaired
autophagy in sCJD, as observed in other neurodegenera-
tive diseases [75], since we detected the accumulation of
autophagic vacuoles (autophagosomes or autophagolyso-
somes), abnormal lysosomes and auto-lysosomes. This
would be in agreement with increased LC3-II levels,





Fig. 9 Activation of Calpain-Cathepsin in sCJD at pre-clinical stages of the disease. a qPCR analysis of expression levels of Calpain 1 and Calpain 2 in
the cortex and cerebellum of the tg340-PRNP129MM mice inoculated with at sCJD MM1 at 120, 160, 180 and 210 dpi (10–1 inoculum dilution was
used for animals sacrificed at 210 dpi). Fold Change represents the ratio between animals inoculated with sCJD-MM1 and control homogenates. b
Western-blot and densitometry of Calpain 1, Calpain 2and Cathepsin S in the cortex and cerebellum of control (n = 3) and sCJD MM1 (n = 3) inoculated
tg340-PRNP129MM mice at sCJD MM1 at 120, 160, 180 and 210 dpi (10–1 inoculum dilution was used for in animals sacrificed at 210 dpi). Fold Change
represents the ratio between animals inoculated with sCJD-MM1and control homogenates. c Western-blot analysis of Calpain 1 N-ter, Cystatin C and
Calpastatin in the cortex and cerebellum of control (n = 3) and sCJD MM1 (n = 3) inoculated tg340-PRNP129MM mice at pre-clinical (120dpi) and
clinical (180dpi) stages. Fold change between sCJD MM1 and control inoculated animals is indicated. d qPCR analysis of expression levels of Cathepsin
S in the cortex and cerebellum of the tg340-PRNP129MM mice inoculated with at sCJD MM1 at 120, 160, 180 and 210 dpi (10–1 inoculum dilution
was used for animals sacrificed at 210 dpi). Fold Change represents the ratio between animals inoculated with sCJD-MM1 and control homogenates. e
Western-blot analysis of PK-treated brain extracts from tg340-PRNP129MM mice inoculated with control and sCJD MM1 bran homogenates at 120 and
180 dpi. 180 dpi sample was diluted 1:5. ANOVA test followed by post-test Tukey’s Multiple Comparison Test was used to compare the values from
different groups. P values for the comparisons of the three groups are indicated in the figure:*p < 0.05; **p < 0.01; ***p < 0.001
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reduced autophagosome turnover, due to delayed
trafficking to the lysosomes, or impaired lysosomal
proteolytic activity. This may result from an overload
of the autophagy system due to the intracellular accu-
mulation of misfolded PrP and lysosomal rupture.
Eventually, impaired autophagy will probably impede
the clearance of protein aggregates and damaged cell
organelles, fuelling oxidative stress mechanisms.
Another consequence of intracellular Ca2+ overload
and Calpain activation is the pathological deregulation
of Cathepsins, and especially of Cathepsin S due to
its stability at a neutral or slightly alkaline pH, thus
retaining most of its activity outside the lysosome
[53]. Our study unveiled a dual neural cell-type spe-
cific role for Cathepsin S during prion pathogenesis
in neurons and microglial cells. While lysosomal-
released neuronal Cathepsin S contributes to prion
neurotoxicity, the precise role of overexpressed
Cathepsin S in microglia remains to be known.
Microglial cells are able to release Cathepsin S into
the extracellular space which can remove protein
aggregates as a neuroprotective mechanism for PrPSc
clearance [7, 22]. Indeed, our data demonstrates a
strong interaction between PrP and Cathepsin S in
sCJD brain, suggesting that Cathepsin S could be part
of the PrPSc aggregated complexes. However, Cathe-
psin S also could play a neurotoxic function inducing
neuronal death through unregulated degradation of
extracellular matrix proteins [69]. The potential dual
role of Cathepsin S in prion pathogenesis may be
even more complex since degradation of extracellular
matrix proteins is a functional mechanism for cell mi-
gration, thus Cathepsin S may assist the migration of
microglia [42], potentially enhancing microglia
mobilization to cope with PrPSc accumulation. Of
interest, Cathepsin S overexpression is not a general
feature of neurodegenerative processes since only
slight mRNA upregulation was detected in early AD
stages and in PD/LBD cases, thus our work sets an
important basis for future studies addressing the true
contribution of Cathepsin S in the neuroinflammation
processes associated with sCJD pathogenesis.
Fig. 10 Proposed Calpain-Cathepsin S axis activation in sCJD. As a consequence of increased neuronal intracellular Ca2+ concentration in sCJD a broad
range of pathologically related events occur such as i) direct or indirect alteration of gene expression patterns and ii) over activation of non-lysosomal
cysteine proteases Calpains. On one side, pathological Calpain activity may cleave PrP, enhancing its misfolded conformation and enhancing prion
seeding in new conversion cycles. On the other hand, Calpain compromise lysosomal membrane integrity, and as a consequence, Cathepsin proteases
are liberated in the cytoplasm. Calpains and proteases with activity at neutral pH, such as Cathepsin S, unspecifically cleave cellular substrates and
structures, interfering with physiological cellular functions. When plasma membrane is compromised, the cellular content is released into the
extracellular space. Additionally, Cathepsin S expression is overexpressed in microglial cells as a consequence of chronic neuroinflammation
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Conclusions
Altogether our study demonstrates that destabilization of
neuronal Ca2+ homeostasis in sCJD could be one of the up-
stream and early events leading to the rapid development
of the prion disease pathology, in which aberrant Calpain-
Cathepsin axis activation would be a key event in the
spread and activation of multiple prion disease-related
pathological mechanisms (Fig. 10). These findings contrib-
ute to a better understanding of molecular mechanisms as-
sociated with the development of human prion disease
pathogenesis and suggest that Ca2+ channel blocking may
be a relevant therapeutic strategy as suggested for other
neurodegenerative disorders associated with Ca2+ alter-
ations such as AD [3, 8, 76]. Importantly, therapeutic inter-
vention would require the definition of very primary
causative mechanisms leading to altered Ca2+ homeostasis,
which in turn unchain the cascade of molecular patho-
logical events, before neuronal damage spreads.
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Additional file 1: Table S1. List of Taqman assays used in this study.
(PPTX 53 kb)
Additional file 2: Figure S1. Partial UPR activation in the frontal cortex of
sCJD cases. (A) Western-blot and densitometric analysis of UPR proteins CHOP,
ATF4, P-IRE-1, IRE-1, XBP1 and ATF6 in the frontal cortex of control and sCJD
MM1 cases. (B) Immunohistochemical detection of CHOP in the frontal cortex
of control and sCJD MM1 cases. (B) Immunohistochemical detection of CHOP
in the cortex of control and sCJD MM1 inoculated tg340-PRNP129MM mice.
Brain slices were counterstained with DAPI. (PPTX 4 kb)
Additional file 3: Figure S2. ER stress in the frontal cortex of sCJD
cases. ER stress and Ca2+ induced genes in sCJD MM1 by (A) Western-blot
(grp78, hsp27, BDNF, Fas and Bcl-2) and (B) Bcl-2/Bax ratio in the frontal
cortex of control and sCJD MM1 cases obtained from the densitometric
analysis of both proteins detected by western-blot analysis. Unpaired t-test
(95% CI) was used for the comparisons of the two groups. *p < 0.05;
**p < 0.01; ***p < 0.001. (PPTX 130 kb)
Additional file 4: Figure S3. Calpain substrates levels in sCJD. (A) qPCR
analysis of CAPNS1/CAPN4 in the frontal cortex and cerebellum of controls
and sCJD MM and VV2 cases. (B) Western-blot and densitometry analysis
of Neurofilament Light (NF-L) and γ-Tubulin in the frontal cortex and
cerebellum of control, sCJD MM1 and sCJD VV2 cases. ANOVA test followed
by post-test Tukey’s Multiple Comparison Test was used to compare the
values from different groups. P values for the comparisons of the three groups
are indicated in the figure:*p< 0.05; **p< 0.01; ***p< 0.001. (PPTX 111 kb)
Additional file 5: Figure S4. Alteration of autophagy related genes in
sCJD. (A) Altered expression of genes involved in autophagy in the cortex
of the tg340-PRNP129MM mice at 120 (pre-clinical) and 180 (clinical) days
after inoculation with sCJD MM1 brain homogenates. (B) qPCR analysis of
the autophagy activators hspa8 and hspb8 in the sCJD infected tg340-
PRNP129MM mice at 180 dpi. (C) Western.-blot and densitometric analysis of the
autophagy related proteins DJ-1, LC3, ATG5 and LAMP2 in the frontal cortex
of control and sCJD MM1 and sCJD VV2 cases. (D) qPCR analysis of the
autophagy-related genes HSPA8, HSPB8, PARK (DJ-1) and LAMP2 in the frontal
cortex of control and sCJD MM1 and sCJDVV2 cases. Unpaired t-test (95% CI)
was used for the comparisons of the two groups. ANOVA test followed by
post-test Tukey’s Multiple Comparison Test was used to compare the values
from different groups. P values for the comparisons of the three groups are in-
dicated in the figure:*p< 0.05; **p< 0.01; ***p< 0.001. (PPTX 244 kb)
Additional file 6: Figure S5. Increased rPrP aggregation induced by sCJD
brain homogenates. Recombinant prion protein was incubated with brain
homogenates from control and sCJD brains (n= 4) and subjected to Western-
blot with PrP SAF70 antibody. (PPTX 195 kb)
Additional file 7: Figure S6. Inhibition of RT-QuIC reaction by Doxycycline.
RT-QuIC assay performed in the presence of sCJD brain homogenates (n= 3)
as seeding material, previously treated with recombinant Calpain in the pres-
ence (+DOX) of absence (−DOX) of Doxycycline (DOX). Relative Fluorescence
Units (RFU) are shown. (PPTX 47 kb)
Additional file 8: Figure S7. Cathepsin S and GAPDH levels in
lysosomal and cytoplasmic enriched fractions derived from prion protein
peptide treatment. (PPTX 88 kb)
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